Current Report Filing (8-k)
March 01 2022 - 05:28PM
Edgar (US Regulatory)
0001642159 false 0001642159 2022-02-23
2022-02-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
February 23, 2022
SIGYN THERAPEUTICS, INC. |
(Exact
Name of Registrant as Specified in Its Charter) |
Delaware |
|
333-204486 |
|
47-2573116 |
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2468 Historic Decatur Road, |
|
|
Suite 140
San Diego,
California
|
|
92106 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
619.368.2000
Prior address and phone number:
2468 Historic Decatur Road, Suite 140 |
|
|
San Diego, CA |
|
92106 |
(Address
of principal executive offices) |
|
(Zip
Code) |
619.353.080072
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
None |
|
None |
|
None |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
As
used herein, the terms, “we,” “us,” “our,” and the “Company” refers
to Sigyn Therapeutics, Inc., a Delaware corporation and its
subsidiaries, unless otherwise stated.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Form 8-K and other reports filed by Sigyn Therapeutics, Inc.
(“Sigyn” or the “Company”) from time to time with the
Securities and Exchange Commission (collectively, the
“Filings”) contain or may contain forward looking statements
and information that are based upon beliefs of, and information
currently available to, the Company’s management as well as
estimates and assumptions made by the Company’s management. When
used in the filings the words “anticipate”, “believe”, “estimate”,
“expect”, “future”, “intend”, “plan” or the negative of these terms
and similar expressions as they relate to the Company or Company’s
management identify forward looking statements. Such statements
reflect the current view of the Company with respect to future
events and are subject to risks, uncertainties, assumptions and
other factors relating to the Company’s industry, the Company’s
operations and results of operations and any businesses that may be
acquired by the Company. Should one or more of these risks or
uncertainties materialize, or should the underlying assumptions
prove incorrect, actual results may differ significantly from those
anticipated, believed, estimated, expected, intended or
planned.
Although
the Company’s management believes that the expectations reflected
in the forward looking statements are reasonable, the Company
cannot guarantee future results, levels of activity, performance or
achievements. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend
to update any of the forward-looking statements to conform these
statements to actual results. The following discussion should be
read in conjunction with the Company’s pro forma financial
statements and the related notes filed with this Form
8-K.
Item
8.01 Other Information.
On
February 23, 2022, Sigyn Therapeutics, Inc. issued a press release
entitled “Sigyn Therapeutics™ Announces Completion of Animal
Studies”, a copy of which is attached hereto as Exhibit
99.1.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
SIGYN
THERAPEUTICS, INC. |
|
|
Date:
March 1, 2022 |
By: |
/s/
James A. Joyce |
|
|
James
A. Joyce, Chairman and CEO |
Sigyn Therapeutics (QB) (USOTC:SIGY)
Historical Stock Chart
From Jan 2023 to Feb 2023
Sigyn Therapeutics (QB) (USOTC:SIGY)
Historical Stock Chart
From Feb 2022 to Feb 2023